US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
EP0758329A1
(en)
*
|
1994-05-05 |
1997-02-19 |
MERCK SHARP & DOHME LTD. |
Morpholine derivatives and their use as antagonists of tachikinins
|
US5824678A
(en)
*
|
1994-08-15 |
1998-10-20 |
Merck Sharp & Dohme Ltd. |
Morpholine derivatives and their use as therapeutic agents
|
GB9417956D0
(en)
*
|
1994-09-02 |
1994-10-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9426104D0
(en)
*
|
1994-12-23 |
1995-02-22 |
Merck Sharp & Dohme |
Use of surfactants and emulsions
|
GB9505491D0
(en)
*
|
1995-03-18 |
1995-05-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9513972D0
(en)
*
|
1995-07-08 |
1995-09-06 |
Merck Sharp & Dohme |
Pharmaceutical compositions
|
GB9523244D0
(en)
*
|
1995-11-14 |
1996-01-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5891875A
(en)
*
|
1996-05-20 |
1999-04-06 |
Eli Lilly And Company |
Morpholinyl tachykinin receptor antagonists
|
CA2260269A1
(en)
|
1996-07-17 |
1998-01-22 |
Merck & Co., Inc. |
Alteration of circadian rhythmicity with a tachykinin antagonist
|
US6117855A
(en)
|
1996-10-07 |
2000-09-12 |
Merck Sharp & Dohme Ltd. |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
|
DE69732492T2
(de)
*
|
1996-12-02 |
2006-03-30 |
Merck Sharp & Dohme Ltd., Hoddesdon |
Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
|
US6100256A
(en)
*
|
1996-12-02 |
2000-08-08 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
|
WO1998024438A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating major depressive disorders
|
WO1998024440A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating stress disorders
|
CA2273806A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating substance use disorders
|
CA2273809A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating movement disorders
|
US5977104A
(en)
*
|
1996-12-02 |
1999-11-02 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
AU729708B2
(en)
*
|
1996-12-02 |
2001-02-08 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating severe anxiety disorders
|
DE69733148T2
(de)
*
|
1996-12-02 |
2006-02-02 |
Merck Sharp & Dohme Ltd., Hoddesdon |
Die verwendung von nk-1 rezeptorantagonisten für die behandlung von kognitiven störungen
|
AU732633B2
(en)
*
|
1996-12-02 |
2001-04-26 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating schizophrenic disorders
|
US6114315A
(en)
*
|
1996-12-02 |
2000-09-05 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
|
CA2273351A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating sexual dysfunction
|
WO1998024443A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating bipolar disorders
|
US6613765B1
(en)
|
1996-12-02 |
2003-09-02 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
GB9700555D0
(en)
*
|
1997-01-13 |
1997-03-05 |
Merck Sharp & Dohme |
Therapeutic agents
|
EP0977572A1
(en)
*
|
1997-04-24 |
2000-02-09 |
Merck Sharp & Dohme Ltd. |
Use of nk-1 receptor antagonists for treating eating disorders
|
WO1999007375A1
(en)
*
|
1997-08-04 |
1999-02-18 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
CA2298777A1
(en)
*
|
1997-08-04 |
1999-02-18 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating mania
|
GB9716457D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
US6156749A
(en)
*
|
1997-12-01 |
2000-12-05 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating movement disorders
|
US5972938A
(en)
*
|
1997-12-01 |
1999-10-26 |
Merck & Co., Inc. |
Method for treating or preventing psychoimmunological disorders
|
US6087348A
(en)
*
|
1997-12-01 |
2000-07-11 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating stress disorders
|
US6271230B1
(en)
|
1997-12-01 |
2001-08-07 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating cognitive disorders
|
GB9810092D0
(en)
*
|
1998-05-11 |
1998-07-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
WO1999064006A1
(en)
*
|
1998-06-11 |
1999-12-16 |
Merck Sharp & Dohme Limited |
Use of a nk-1 receptor antagonist for treating psychiatric disorders
|
GB9812662D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
GB9812617D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
GB9812664D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
JP2002517448A
(ja)
*
|
1998-06-11 |
2002-06-18 |
メルク シャープ エンド ドーム リミテッド |
精神障害の治療用nk−1受容体アンタゴニストの使用
|
GB9813025D0
(en)
*
|
1998-06-16 |
1998-08-12 |
Merck Sharp & Dohme |
Chemical synthesis
|
GB9816897D0
(en)
*
|
1998-08-04 |
1998-09-30 |
Merck Sharp & Dohme |
Therapeutic use
|
CA2348526A1
(en)
*
|
1998-10-30 |
2000-05-11 |
Merck & Co., Inc. |
Process for the preparation of 2-(r)-(1- (r)-(3,5-bis (trifluoromethyl) phenyl)ethoxy) -4-((5-dimethylaminomethyl) -1,2,3-triazol -4-yl)methyl) -3-(s)-(4- fluorophenyl) morpholine
|
AU1230000A
(en)
*
|
1998-10-30 |
2000-05-22 |
Merck & Co., Inc. |
Linear process for the preparation of a morpholine compound
|
SE1035115T5
(sv)
*
|
1999-02-24 |
2015-08-04 |
Hoffmann La Roche |
4-fenylpyridin-derivat och deras anvaendning som NK-1 receptor-antagonister
|
CZ20013046A3
(cs)
|
1999-02-24 |
2002-02-13 |
F. Hoffmann-La Roche Ag |
Fenylové a pyridinylové deriváty
|
CA2364662C
(en)
|
1999-02-24 |
2009-10-20 |
F. Hoffmann-La Roche Ag |
3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
|
US6291465B1
(en)
|
1999-03-09 |
2001-09-18 |
Hoffmann-La Roche Inc. |
Biphenyl derivatives
|
TW550258B
(en)
|
1999-05-31 |
2003-09-01 |
Hoffmann La Roche |
4-phenyl-pyrimidine derivatives
|
JO2308B1
(en)
|
1999-05-31 |
2005-09-12 |
اف. هوفمان- لاروش أيه جي |
Derivatives of phenylpyrmidine
|
AU1343901A
(en)
|
1999-10-29 |
2001-05-14 |
Merck & Co., Inc. |
Polymorphic form of a tachykinin receptor antagonist
|
PT1103545E
(pt)
*
|
1999-11-29 |
2004-03-31 |
Hoffmann La Roche |
2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
|
US6452001B2
(en)
|
2000-05-25 |
2002-09-17 |
Hoffmann-La Roche Inc. |
Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
|
US6482829B2
(en)
|
2000-06-08 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
|
AR030284A1
(es)
|
2000-06-08 |
2003-08-20 |
Merck & Co Inc |
Proceso para la sintesis de (2r, 2-alfa-r,3a) -2-[1-(3,5-bis(trifluorometil) fenil) etoxi]-3-(4-fluorofenil)-1,4-oxazina; dicho compuesto y sus formas polimorficas
|
AU2001269749A1
(en)
*
|
2000-06-09 |
2001-12-24 |
Merck And Co., Inc. |
Trans-glycosidation process for the synthesis of (2r, 2-alpha-r, 3a)-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-3-(4-fluorophenyl)-1,4-oxazine
|
MXPA03000366A
(es)
|
2000-07-14 |
2003-05-27 |
Hoffmann La Roche |
N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.
|
TWI287003B
(en)
|
2000-07-24 |
2007-09-21 |
Hoffmann La Roche |
4-phenyl-pyridine derivatives
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
GB0020721D0
(en)
*
|
2000-08-22 |
2000-10-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
YU39503A
(sh)
|
2000-11-22 |
2006-05-25 |
F. Hoffmann-La Roche Ag. |
Derivati pirimidina
|
US6642226B2
(en)
|
2001-02-06 |
2003-11-04 |
Hoffman-La Roche Inc. |
Substituted phenyl-piperidine methanone compounds
|
US6849624B2
(en)
|
2001-07-31 |
2005-02-01 |
Hoffmann-La Roche Inc. |
Aromatic and heteroaromatic substituted amides
|
US6638981B2
(en)
|
2001-08-17 |
2003-10-28 |
Epicept Corporation |
Topical compositions and methods for treating pain
|
DE602004007486T2
(de)
|
2003-01-31 |
2008-04-30 |
F. Hoffmann-La Roche Ag |
Neue kristallmodifikation von 2-(3,5-bis-trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-thiomorpholin-4-yl)-4(4-fluor-2-methyl-phenyl)-pyridin-3-yl-n-methyl-isobutyramid
|
PL1643998T3
(pl)
|
2003-07-03 |
2008-01-31 |
Hoffmann La Roche |
Podwójni antagoniści NK1/NK3 do leczenia schizofrenii
|
US7288658B2
(en)
*
|
2003-07-15 |
2007-10-30 |
Hoffmann-La Roche Inc. |
Process for preparation of pyridine derivatives
|
ES2246687B2
(es)
|
2004-02-11 |
2006-11-16 |
Miguel Muñoz Saez |
Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
|
NZ552397A
(en)
|
2004-07-15 |
2011-04-29 |
Amr Technology Inc |
Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
AU2005320547B2
(en)
|
2004-12-27 |
2009-02-05 |
Eisai R & D Management Co., Ltd. |
Method for stabilizing anti-dementia drug
|
ES2329827T3
(es)
|
2005-02-22 |
2009-12-01 |
F. Hoffmann-La Roche Ag |
Antagonistas de nk1.
|
PT1863767E
(pt)
|
2005-03-23 |
2009-03-27 |
Hoffmann La Roche |
Metabolitos para antagonistas de nk-1 para vómitos
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
KR20080044840A
(ko)
|
2005-07-15 |
2008-05-21 |
에이엠알 테크놀로지, 인크. |
아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
|
MY143784A
(en)
*
|
2005-09-23 |
2011-07-15 |
Hoffmann La Roche |
Novel dosage formulation
|
EP1940842B1
(en)
|
2005-09-29 |
2012-05-30 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
EP2266980A1
(en)
*
|
2005-10-05 |
2010-12-29 |
Ranbaxy Laboratories Limited |
Polymorphic form of aprepitant intermediate
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
JP5489333B2
(ja)
|
2006-09-22 |
2014-05-14 |
メルク・シャープ・アンド・ドーム・コーポレーション |
脂肪酸合成阻害剤を用いた治療の方法
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
PL2336120T3
(pl)
|
2007-01-10 |
2014-12-31 |
Msd Italia Srl |
Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
|
US8093268B2
(en)
|
2007-01-24 |
2012-01-10 |
Glaxo Group Limited |
Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
|
EP2145884B1
(en)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledione derivative
|
CA2682506C
(en)
|
2007-04-20 |
2016-05-24 |
F. Hoffmann-La Roche Ag |
Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
|
AU2008269154B2
(en)
|
2007-06-27 |
2014-06-12 |
Merck Sharp & Dohme Llc |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
EP2185540B1
(en)
|
2007-08-07 |
2011-07-20 |
F. Hoffmann-La Roche AG |
Pyrrolidine aryl-ether as nk3 receptor antagonists
|
CA2716080C
(en)
|
2008-02-20 |
2016-12-13 |
Targia Pharmaceuticals |
Cns pharmaceutical compositions and methods of use
|
JP2011515343A
(ja)
|
2008-03-03 |
2011-05-19 |
タイガー ファーマテック |
チロシンキナーゼ阻害薬
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
EP2429295B1
(en)
|
2009-05-12 |
2013-12-25 |
Albany Molecular Research, Inc. |
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
|
WO2010132442A1
(en)
|
2009-05-12 |
2010-11-18 |
Albany Molecular Reserch, Inc. |
7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
|
EP2429293B1
(en)
|
2009-05-12 |
2014-10-29 |
Bristol-Myers Squibb Company |
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
|
WO2011046771A1
(en)
|
2009-10-14 |
2011-04-21 |
Schering Corporation |
SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
|
US8487102B2
(en)
|
2010-04-20 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
ES2376564B1
(es)
|
2010-08-12 |
2013-01-24 |
Manuel Vicente Salinas Martín |
Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
|
CA2807307C
(en)
|
2010-08-17 |
2021-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
ES2663009T3
(es)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
JP2014514321A
(ja)
|
2011-04-21 |
2014-06-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
インスリン様増殖因子1受容体阻害剤
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
EP2837381A4
(en)
|
2011-12-13 |
2015-12-09 |
Servicio Andaluz De Salud |
USE OF AGENTS MODIFYING THE PERITUMORAL ENVIRONMENT FOR THE TREATMENT OF CANCER
|
EP3358013B1
(en)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Erk阻害剤である新規化合物
|
BR112015012295A8
(pt)
|
2012-11-28 |
2023-03-14 |
Merck Sharp & Dohme |
Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
|
MX2015008196A
(es)
|
2012-12-20 |
2015-09-16 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
ES2493693B1
(es)
|
2013-02-11 |
2015-07-07 |
Servicio Andaluz De Salud |
Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
ES2541870B1
(es)
|
2013-12-27 |
2016-05-12 |
Servicio Andaluz De Salud |
Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
|
EP3091977A2
(en)
*
|
2013-12-30 |
2016-11-16 |
Oncoprevent GmbH |
Neurokinin-1 receptor antagonists for use in a method of prevention of cancer
|
TW201613888A
(en)
|
2014-09-26 |
2016-04-16 |
Helsinn Healthcare Sa |
Crystalline forms of an NK-1 antagonist
|
US10005803B2
(en)
|
2015-10-06 |
2018-06-26 |
Helsinn Healthcare Sa |
Crystalline forms of fosnetupitant
|
WO2017211663A1
(en)
|
2016-06-06 |
2017-12-14 |
Helsinn Healthcare Sa |
Physiologically balanced injectable formulations of fosnetupitant
|
WO2018071283A1
(en)
|
2016-10-12 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Kdm5 inhibitors
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3706747A4
(en)
|
2017-11-08 |
2021-08-04 |
Merck Sharp & Dohme Corp. |
PRMT5 INHIBITORS
|
EP3833668A4
(en)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
PRMT5 INHIBITORS
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|